• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial.

作者信息

Eichacker Peter Q, Danner Robert L, Suffredini Anthony F, Cui Xizhong, Natanson Charles

出版信息

Crit Care Med. 2005 Oct;33(10):2426-8. doi: 10.1097/01.ccm.0000183002.26587.ff.

DOI:10.1097/01.ccm.0000183002.26587.ff
PMID:16215410
Abstract
摘要

相似文献

1
Reassessing recombinant human activated protein C for sepsis: time for a new randomized controlled trial.重新评估重组人活化蛋白C治疗脓毒症：开展新的随机对照试验的时候了。
Crit Care Med. 2005 Oct;33(10):2426-8. doi: 10.1097/01.ccm.0000183002.26587.ff.
2
Drotrecogin alfa on trial.活化蛋白C进行试验。
Lancet Infect Dis. 2009 Jan;9(1):2-3. doi: 10.1016/S1473-3099(08)70286-X.
3
Risks and benefits of activated protein C treatment for severe sepsis.活化蛋白C治疗严重脓毒症的风险与益处
N Engl J Med. 2002 Sep 26;347(13):1027-30. doi: 10.1056/NEJMsb020574.
4
Assessing the use of activated protein C in the treatment of severe sepsis.评估活化蛋白C在严重脓毒症治疗中的应用。
N Engl J Med. 2002 Sep 26;347(13):1030-4. doi: 10.1056/NEJMsb021512.
5
Kigris. FDA approves first biologic for sepsis.基格里斯。美国食品药品监督管理局批准首款用于治疗败血症的生物制剂。
Nursing. 2002 Feb;32(2):18.
6
Should we be using activated protein C to treat severe sepsis?我们应该使用活化蛋白C来治疗严重脓毒症吗？
Br J Hosp Med (Lond). 2009 Aug;70(8):484. doi: 10.12968/hmed.2009.70.8.43548.
7
Recombinant human activated protein C in sepsis: inconsistent trial results, an unclear mechanism of action, and safety concerns resulted in labeling restrictions and the need for phase IV trials.重组人活化蛋白C用于脓毒症治疗：试验结果不一致、作用机制不明以及安全性问题导致了标签限制和开展IV期试验的必要性。
Crit Care Med. 2003 Jan;31(1 Suppl):S94-6. doi: 10.1097/00003246-200301001-00013.
8
Severe sepsis and therapy with activated protein C.严重脓毒症与活化蛋白C治疗
N Engl J Med. 2005 Sep 29;353(13):1398-400. doi: 10.1056/NEJMe058160.
9
[Recombinant activated protein C: from evidence to clinical practice. Clinical practice guidelines for the use of activated proteins C in the treatment of severe sepsis].[重组活化蛋白C：从证据到临床实践。活化蛋白C用于治疗严重脓毒症的临床实践指南]
Ugeskr Laeger. 2004 Mar 8;166(11):997-1002.
10
Activated protein C: do more survive?活化蛋白C：更多患者能存活吗？
Intensive Care Med. 2006 Apr;32(4):605-7; author reply 610-2. doi: 10.1007/s00134-006-0087-8. Epub 2006 Mar 1.

引用本文的文献

1
Medical guidelines and performance measures: the need to keep them free of industry influence.医学指南与绩效指标：使其免受行业影响的必要性。
Mens Sana Monogr. 2008 Jan;6(1):22-8. doi: 10.4103/0973-1229.33005.
2
An update on activated protein C (xigris) in the management of sepsis.关于活化蛋白C（Xigris）在脓毒症治疗中的最新进展。
P T. 2010 Sep;35(9):504-29.
3
Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies.对脓毒症中活化蛋白C给药潜在益处和风险的深入认识：临床前和临床研究综述
Biologics. 2009;3:391-406. doi: 10.2147/btt.2009.3547. Epub 2009 Sep 15.
4
Can we predict the effects of NF-kappaB inhibition in sepsis? Studies with parthenolide and ethyl pyruvate.我们能否预测 NF-κB 抑制在脓毒症中的作用？以小白菊内酯和丙酮酸乙酯为例的研究。
Expert Opin Investig Drugs. 2009 Aug;18(8):1047-60. doi: 10.1517/13543780903018880.
5
Role of clinical evaluation committees in sepsis trials: from 'valid cohort' assessment to subgroup analysis.临床评估委员会在脓毒症试验中的作用：从“有效队列”评估到亚组分析。
Crit Care. 2009;13(2):124. doi: 10.1186/cc7686. Epub 2009 Mar 18.
6
Editors' comments on a new trial of activated protein C for persistent septic shock.编辑对一项关于活化蛋白C治疗持续性感染性休克新试验的评论。
Intensive Care Med. 2008 Nov;34(11):1948-9. doi: 10.1007/s00134-008-1303-5. Epub 2008 Oct 7.
7
Mechanisms of sepsis and insights from clinical trials.脓毒症的发病机制及临床试验的见解。
Drug Discov Today Dis Mech. 2007;4(2):83-93. doi: 10.1016/j.ddmec.2007.10.004.
8
Why are clinicians not embracing the results from pivotal clinical trials in severe sepsis? A bayesian analysis.为何临床医生不接受严重脓毒症关键临床试验的结果？一项贝叶斯分析。
PLoS One. 2008 May 28;3(5):e2291. doi: 10.1371/journal.pone.0002291.
9
How many patients with severe sepsis are needed to confirm the efficacy of drotrecogin alfa activated? A Bayesian design.需要多少例严重脓毒症患者才能证实活化蛋白C（drotrecogin alfa）的疗效？一项贝叶斯设计。
Intensive Care Med. 2008 Oct;34(10):1804-11. doi: 10.1007/s00134-008-1159-8. Epub 2008 May 27.
10
Potential interventions in sepsis-related acute kidney injury.脓毒症相关急性肾损伤的潜在干预措施。
Clin J Am Soc Nephrol. 2008 Mar;3(2):531-44. doi: 10.2215/CJN.03830907. Epub 2008 Jan 30.